Latest Hydrix (Asx:Hyd) News

Hydrix Limited reports a robust quarter with $3.35 million in sales, a 7% revenue increase, and a strong international client base, while advancing US market ventures.

Hydrix Limited will have its trading suspension lifted on 13 October 2025 following the release of its audited financial statements for FY2025. Investors await clarity on the company’s financial health as it returns to the ASX.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Hydrix Limited has responded to an ASX query following a sudden surge in its share price and trading volume, denying any undisclosed material information and reaffirming compliance with listing rules.

Hydrix Limited narrowed its FY2025 loss to $2.92 million, driven by significant cost reductions and steady revenue from expanding international medtech clients. Despite ongoing challenges in sales cycles and funding, the company remains focused on innovation and strategic investments.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

Hydrix Limited reports back-to-back profitable quarters driven by strong margins and cost efficiencies, underpinned by a robust $40 million sales opportunity pipeline in cardiac and medtech sectors.

Hydrix Limited has extended its contract with Paul Hartmann AG, adding $2.8 million in revenue and reinforcing its international growth strategy.